Literature DB >> 18075845

Polycystic ovary syndrome: a follow-up study on diabetes mellitus, cardiovascular disease and malignancy 15-25 years after ovarian wedge resection.

Ottar Lunde1, Tom Tanbo.   

Abstract

The aim of the present study was to examine the occurrence of possibly associated diseases in 149 women with polycystic ovary syndrome (PCOS) 15-25 years after ovarian wedge resection. Diabetes mellitus was the only associated disease which showed a significantly increased occurrence. No significant change in cancers specific for the female gender was seen. Likewise, the relative risk of cardiovascular disease was not affected. However, the power of the statistical test was low. This long-term study indicates increased risk of diabetes mellitus in PCOS patients. The study group is too small to give any conclusions about other possibly associated diseases. Family histories, however, revealed that associated diseases are related to genetic disposition rather than to PCOS per se.

Entities:  

Mesh:

Year:  2007        PMID: 18075845     DOI: 10.1080/09513590701705189

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  11 in total

1.  Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia.

Authors:  Erica T Wang; Ronit Calderon-Margalit; Marcelle I Cedars; Martha L Daviglus; Sharon S Merkin; Pamela J Schreiner; Barbara Sternfeld; Melissa Wellons; Stephen M Schwartz; Cora E Lewis; O Dale Williams; David S Siscovick; Kirsten Bibbins-Domingo
Journal:  Obstet Gynecol       Date:  2011-01       Impact factor: 7.661

2.  Menstrual irregularity and cardiovascular mortality.

Authors:  Erica T Wang; Piera M Cirillo; Eric Vittinghoff; Kirsten Bibbins-Domingo; Barbara A Cohn; Marcelle I Cedars
Journal:  J Clin Endocrinol Metab       Date:  2010-10-27       Impact factor: 5.958

Review 3.  The Diabetes-Cardiovascular Connection in Women: Understanding the Known Risks, Outcomes, and Implications for Care.

Authors:  Eric K Broni; Chiadi E Ndumele; Justin B Echouffo-Tcheugui; Rita R Kalyani; Wendy L Bennett; Erin D Michos
Journal:  Curr Diab Rep       Date:  2022-02-14       Impact factor: 4.810

Review 4.  HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome?

Authors:  Pinar H Kodaman; Antoni J Duleba
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Statins in the treatment of polycystic ovary syndrome.

Authors:  Pinar H Kodaman; Antoni J Duleba
Journal:  Semin Reprod Med       Date:  2008-01       Impact factor: 1.303

Review 6.  Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  John A Barry; Mallika M Azizia; Paul J Hardiman
Journal:  Hum Reprod Update       Date:  2014-03-30       Impact factor: 15.610

7.  Risk of Cardiovascular and Cerebrovascular Events in Polycystic Ovarian Syndrome Women: A Meta-Analysis of Cohort Studies.

Authors:  Jun Zhang; Ji-Hong Xu; Qian-Qin Qu; Guo-Qing Zhong
Journal:  Front Cardiovasc Med       Date:  2020-11-12

8.  Trend of Cardio-Metabolic Risk Factors in Polycystic Ovary Syndrome: A Population-Based Prospective Cohort Study.

Authors:  Fahimeh Ramezani Tehrani; Seyed Ali Montazeri; Farhad Hosseinpanah; Leila Cheraghi; Hadi Erfani; Maryam Tohidi; Fereidoun Azizi
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

9.  Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis.

Authors:  Luqian Zhao; Zhigang Zhu; Huiling Lou; Guodong Zhu; Weimin Huang; Shaogang Zhang; Feng Liu
Journal:  Oncotarget       Date:  2016-06-07

10.  Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression.

Authors:  Mina Amiri; Fahimeh Ramezani Tehrani; Samira Behboudi-Gandevani; Razieh Bidhendi-Yarandi; Enrico Carmina
Journal:  Reprod Biol Endocrinol       Date:  2020-03-17       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.